SCHEMBL516298

SCHEMBL516298

C=C(C(=O)c1ccccc1O)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 6/20 0.54
KDM4E B2RXH2 6/20 0.54
SMN1; SMN2 Q16637 4/20 0.54
ALDH1A1 P00352 3/20 0.54
CA12 O43570 1/20 0.54
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
HMGB1 P09429 1/20 0.54
CA4 P22748 1/20 0.54
CA6 P23280 1/20 0.54
CA7 P43166 1/20 0.54
CA9 Q16790 1/20 0.54
NAPRT Q6XQN6 1/20 0.54
CA14 Q9ULX7 1/20 0.54
MAPT P10636 4/20 0.50
CYP3A4 P08684 1/20 0.50
HSD17B10 Q99714 3/20 0.47
TSHR P16473 2/20 0.47
GSTA1 P08263 1/20 0.46
LIG1 P18858 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25234080 0.85 HNF4A (0.51) HPGDKDM4ESMN1; SMN2ALDH1A1CA12
SCHEMBL10934521 0.83 ALDH1A1 (0.52) HPGDKDM4ESMN1; SMN2ALDH1A1CYP3A4
SCHEMBL11664153 0.82 ALDH1A1 (0.58) HPGDKDM4ESMN1; SMN2ALDH1A1CA12
SCHEMBL25265133 0.81 LIG1 (0.41) HPGDKDM4ESMN1; SMN2ALDH1A1CA12
SCHEMBL9715736 0.81 HPGD (0.48) HPGDKDM4ESMN1; SMN2ALDH1A1CA12
SCHEMBL967919 0.81 CES2 (0.64) HPGDKDM4ESMN1; SMN2ALDH1A1CA12
SCHEMBL761381 0.78 CES2 (0.65) HPGDSMN1; SMN2ALDH1A1CA12CA1
SCHEMBL9797513 0.78 KDM4E (0.67) HPGDKDM4ESMN1; SMN2ALDH1A1CA12
SCHEMBL29861559 0.78 KDM4E (0.67) HPGDKDM4ESMN1; SMN2ALDH1A1CA12
SCHEMBL928902 0.77 KDM4E (0.60) HPGDKDM4ESMN1; SMN2ALDH1A1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2473606-B1 Controlling transgene expression across the skin ETH ZUERICH (CH) 2016-06-29 EP disclosed
US-8653046-B2 Controlling transgene expression across the skin ETH ZURICH (CH) 2014-02-18 US disclosed
EP-2473606-A1 CONTROLLING TRANSGENE EXPRESSION ACROSS THE SKIN ETH Zurich (CH) 2012-07-11 EP disclosed
US-20120029074-A1 CONTROLLING TRANSGENE EXPRESSION ACROSS THE SKIN ETH ZURICH (CH) 2012-02-02 US disclosed
WO-2010115583-A1 CONTROLLING TRANSGENE EXPRESSION ACROSS THE SKIN ETH ZURICH (CH) 2010-10-14 WO disclosed
EP-2239326-A1 Controlling transgene expression across the skin ETH Zurich (CH) 2010-10-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120029074-A1 CONTROLLING TRANSGENE EXPRESSION ACROSS THE SKIN REL, CUTA, PTAR1 HPGD 1799/4885KDM4E 794/4885SMN1; SMN2 4673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.